Home Cart Sign in  
Chemical Structure| 1952251-28-3 Chemical Structure| 1952251-28-3

Structure of TAK-659 HCl
CAS No.: 1952251-28-3

Chemical Structure| 1952251-28-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-659 HCl is a selective inhibitor of spleen tyrosine kinase (Syk) with IC50 of 3.2 nM.

Synonyms: TAK-659; TAK-659 hydrochloride; Mivavotinib monohydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TAK-659 HCl

CAS No. :1952251-28-3
Formula : C17H22ClFN6O
M.W : 380.85
SMILES Code : O=C1NCC2=C1C(C3=CN(C)N=C3)=NC(N[C@H]4[C@@H](N)CCCC4)=C2F.[H]Cl
Synonyms :
TAK-659; TAK-659 hydrochloride; Mivavotinib monohydrochloride
MDL No. :MFCD31544322
InChI Key :PTCFBXMEFRIEGV-ZVWHLABXSA-N
Pubchem ID :129626432

Safety of TAK-659 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of TAK-659 HCl

RTK

Isoform Comparison

Biological Activity

Target
  • FLT3

    FLT3, IC50:4.6 nM

  • Syk

    Syk, IC50:3.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MYC cells 1.66 μM 24 hours Inhibited pSYK PMC6106053
Primary AML cells 0.05 µM 7 days Evaluate the antiproliferative effect of TAK-659 on AML cells, showing significantly higher antiproliferative effects in FLT3 mutated patients. PMC9737311
Primary AML cells 0.5 µM 7 days Evaluate the antiproliferative effect of TAK-659 on AML cells, showing significantly higher antiproliferative effects in FLT3 mutated patients. PMC9737311
LMP2A/MYC cells 63 nM 24 hours Totally abrogated pSYK PMC6106053
MYC cells 5 μM 1 hour Totally inhibited baseline pSYK PMC6106053
LMP2A/MYC cells 5 μM 1 hour Totally inhibited baseline pSYK PMC6106053
Primary AML cells 0.05 µM 7 days Evaluate the antiproliferative effect of TAK-659 on AML cells, showing strong antiproliferative effects in all seven patient samples tested. PMC9737311
Primary AML cells 0.5 µM 7 days Evaluate the antiproliferative effect of TAK-659 on AML cells, showing strong antiproliferative effects in all seven patient samples tested. PMC9737311
Jurkat T cells 0.1 μM 1 hour TAK-659 did not affect anti-CD3-induced TCR signaling, including phosphorylation of ZAP-70Tyr319, ZAP-70Tyr493, Itk, Akt, and ERK1/2. PMC5352193

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LMP2A/MYC transgenic mice Oral gavage 100 mg/kg Daily for 10 days Totally abrogated splenomegaly and tumor development PMC6106053
NSG mice Pediatric ALL patient-derived xenograft models Oral 60 mg/kg Once daily for 21 days To evaluate the in vivo efficacy of TAK-659 against pediatric ALL PDXs. Results showed that TAK-659 significantly prolonged the time to event in 6 out of 8 PDXs tested, but only one PDX achieved an objective response. PMC10730772

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.13mL

2.63mL

1.31mL

26.26mL

5.25mL

2.63mL

References

 

Historical Records

Categories